[37] For the PD-L1-targeting antibody MPDL3280A a high predictive impact of PD-L1 expression on tumor-infiltrating immune cells was seen in a phase I study on metastatic bladder cancer [38] as well as in a phase I study including multiple advanced or metastatic cancer types, predominantly NSCLC (ovarian carcinoma, n = 1). Here, CD274 is linked to metastatic malignant neoplasm.